Funding Opportunity Number: RFA-AI-12-044
Current Closing Date for Applications: Mar 26, 2013
Award Ceiling: $4,000,000
Eligibility: Foreign Institutions are eligible to apply
Project proposals should address NIAID Priority Pathogens (Biodefense)
Project proposals should address NIAID Priority Pathogens (Biodefense)
The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), supports extramural research focused on understanding, controlling and preventing diseases caused by virtually all infectious agents. In response to threats presented by emerging infectious diseases and bioterrorism, the NIAID Division of Microbiology and Infectious Diseases (DMID) has established complementary research programs to facilitate development of medical countermeasures for certain pathogens and toxins.
NIAID invites applications to establish Centers of Excellence for Translational Research (CETR) focused on the development of medical countermeasures and associated platforms/technologies targeting NIAID Emerging and Re-emerging Infectious Diseases (http://www.niaid.nih.gov/topics/emerging/pages/list.aspx), which includes NIAID Category A, B and C Priority Pathogens. For the purposes of this FOA, “translational research” is defined as research and developmental activities focused on transforming basic science outcomes (knowledge, technologies, infrastructure, etc.) into new and innovative approaches for prevention, diagnosis, and treatment of disease. Priority will be given to Centers that address the greatest clinical need. Emphasis will be placed on Centers that integrate current research knowledge and infrastructure with highly innovative and synergistic approaches to facilitate medical countermeasure development, and address related constraints, challenges or barriers to product development, licensure and usage. Clinical trials will not be supported under this program.
NIAID invites applications to establish Centers of Excellence for Translational Research (CETR) focused on the development of medical countermeasures and associated platforms/technologies targeting NIAID Emerging and Re-emerging Infectious Diseases (http://www.niaid.nih.gov/topics/emerging/pages/list.aspx), which includes NIAID Category A, B and C Priority Pathogens. For the purposes of this FOA, “translational research” is defined as research and developmental activities focused on transforming basic science outcomes (knowledge, technologies, infrastructure, etc.) into new and innovative approaches for prevention, diagnosis, and treatment of disease. Priority will be given to Centers that address the greatest clinical need. Emphasis will be placed on Centers that integrate current research knowledge and infrastructure with highly innovative and synergistic approaches to facilitate medical countermeasure development, and address related constraints, challenges or barriers to product development, licensure and usage. Clinical trials will not be supported under this program.
The full announcement is at:
Please contact Paul, Gary, or Lorna in the Research Administration Unit, Office of Research Services (ORS), for information, advice and assistance applying for this research funding opportunity.
